BioCentury | Nov 15, 2019
Product Development

Minerva on the verge in neuropsychiatry with two compounds close to verdict

Minerva Neurosciences is on the precipice of two clinical readouts that could determine whether its founding bet on a pair of neuropsychiatry compounds from Mitsubishi Tanabe has panned out. Neither molecule represents a shift from...
BioCentury | Jun 21, 2019
Company News

June 20 Company Quick Takes: Priority Review for Alexion, Melinta therapies; plus Alimera, Denovo and more

Priority Review for Alexion's Ultomiris sBLA FDA accepted and granted Priority Review to an sBLA from Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) for Ultomiris ravulizumab-cwvz to block complement-mediated thrombotic microangiopathy in patients with atypical hemolytic uremic syndrome....
BioCentury | May 28, 2019
Distillery Therapeutics

Adrenergic receptor inhibitor combo to treat stroke

...DISEASE CATEGORY: Neurology INDICATION: Stroke Mouse studies suggest inhibiting ADRA1, ADRA2 and ADRB could help treat...
...In two mouse models of ischemic stroke, the combination of the ADRA1 antagonist prazosin, the ADRA2...
...monai.hiromu@ocha.ac.jp CONTACT: Hajime Hirase, same affiliaion as above email: hajime.hirase@riken.jp Chris Lieu Riken Adrenergic receptor alpha 1 (ADRA1) Adrenergic receptor alpha 2 (ADRA2) Adrenergic...
BioCentury | Apr 11, 2019
Company News

Ocugen to go public via Histogenics reverse merger

...which are ophthalmic nanoemulsion formulations of brimonidine tartrate, a relatively selective adrenergic receptor α 2 (ADRA2...
BioCentury | Mar 14, 2019
Company News

Tonix's PTSD therapy loses breakthrough therapy designation

FDA rescinded breakthrough therapy designation for Tonix's Tonmya cyclobenzaprine (Sublingual TNX-102) to treat military-related posttraumatic stress disorder (PTSD), saying an interim analysis of the Phase III HONOR trial did not sufficiently support the designation. In...
BioCentury | Feb 1, 2019
Clinical News

Eyenovia planning NDA in 1Q20 for microdose ophthalmic solution to induce mydriasis

Eyenovia Inc. (NASDAQ:EYEN) plans to submit an NDA to FDA in 1Q20 for MicroStat to induce mydriasis (dilation of the pupil) after the product met the primary endpoint in the Phase III MIST-1 trial. MicroStat...
BioCentury | Aug 3, 2018
Clinical News

Tonix stops Phase III of PTSD candidate on lack of separation from placebo

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) said it will stop the Phase III HONOR trial of Tonmya (Sublingual TNX-102) to treat military-related post-traumatic stress disorder (PTSD) after the candidate showed "inadequate separation" from placebo at an...
BioCentury | May 18, 2018
Clinical News

FDA approves US WorldMeds' Lucemyra for opioid withdrawal

...respond to inquiries regarding its launch plans or pricing details. The oral agonist of adrenergic receptor alpha 2 (ADRA2...
...LLC, Louisville, Ky. Product: Lucemyra lofexidine Business: Neurology Chris Lieu BritLofex, Lucemyra, lofexidine Stada Arzneimittel AG US WorldMeds LLC Adrenergic receptor alpha 2 (ADRA2) Addiction...
BioCentury | May 16, 2018
Company News

FDA approves US WorldMeds' Lucemyra for opioid withdrawal

...respond to inquiries regarding its launch plans or pricing details. The oral agonist of adrenergic receptor alpha 2 (ADRA2...
...of new addiction" (see BioCentury Extra, May 14) . Chris Lieu BritLofex, lofexidine Stada Arzneimittel AG US WorldMeds LLC Adrenergic receptor alpha 2 (ADRA2) Addiction Lucemyra...
BioCentury | Apr 13, 2018
Clinical News

Ocugen reports Phase II data for dry eye disease candidate

...3Q18. The product is an ophthalmic nanoemulsion formulation of brimonidine tartrate, a relatively selective adrenergic receptor alpha 2 (ADRA2...
...Molecular target: Adrenergic receptor alpha 2 (ADRA2) Description: Ophthalmic nanoemulsion formulation of brimonidine tartrate, a relatively selective adrenergic receptor alpha 2 (ADRA2...
Items per page:
1 - 10 of 319